In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy

• Main Authors: Shukun Chen, Gerlinde Tauber, Tanja Langsenlehner, Linda Maria Schmölzer, Michaela Pötscher, Sabine Riethdorf, Andra Kuske, Gerd Leitinger, Karl Kashofer, Zbigniew T. Czyż, Bernhard Polzer, Klaus Pantel, Peter Sedlmayr, Thomas Kroneis, Amin El-Heliebi
• Format: Article
• Language: English
• Published: MDPI AG 2019-07-01
• Series: Cancers
• Subjects: circulating tumor cells; in vivo detection; non-metastatic prostate cancer; radiotherapy
• Online Access: https://www.mdpi.com/2072-6694/11/7/933

High-risk non-metastatic prostate cancer (PCa) has the potential to progress into lethal disease. Treatment options are manifold but, given a lack of surrogate biomarkers, it remains unclear which treatment offers the best results. Several studies have reported circulating tumor cells (CTCs) to be a prognostic biomarker in metastatic PCa. However, few reports on CTCs in high-risk non-metastatic PCa are available. Herein, we evaluated CTC detection in high-risk non-metastatic PCa patients using the in vivo CellCollector CANCER01 (DC01) and CellSearch system. CTC counts were analyzed and compared before and after radiotherapy (two sampling time points) in 51 high-risk non-metastatic PCa patients and were further compared according to isolation technique; further, CTC counts were correlated to clinical features. Use of DC01 resulted in a significantly higher percentage of CTC-positive samples compared to CellSearch (33.7% vs. 18.6%; <i>p</i> = 0.024) and yielded significantly higher CTC numbers (range: 0&#8722;15 vs. 0&#8722;5; <i>p</i> = 0.006). Matched pair analysis of samples between two sampling time points showed no difference in CTC counts determined by both techniques. CTC counts were not correlated with clinicopathological features. In vivo enrichment using DC01 has the potential to detect CTC at a higher efficiency compared to CellSearch, suggesting that CTC is a suitable biomarker in high-risk non-metastatic PCa.